Yasheng Pharmaceutical-B (06855) is now up nearly 6%. As of press release, it has risen 5.19% to HK$24.3, with a turnover of HK$23.397,700.
The Zhitong Finance App learned that Yasheng Pharmaceutical-B (06855) is now up nearly 6%. As of press release, it has risen 5.19% to HK$24.3, with a turnover of HK$23.3977 million.
According to the news, Yasheng Pharmaceutical announced that three of the company's preclinical research advances were selected for the 2024 American Association for Cancer Research Annual Meeting (AACR 2024), involving the company's original Class 1 drug olevatinib (trade name: Nelick; R&D code: HQP1351), MDM2-p53 inhibitor APG-115, FAK/ALK/ROS1 triple tyrosine kinase inhibitor APG-2449, and the embryonic outer layer development protein (EED) inhibitor APG-5918. The summary is now published on AACR's official website.
Notably, Yasheng Pharmaceutical announced on February 14 that it has obtained permission from the US Food and Drug Administration (FDA) to conduct a registered phase 3 trial of olevatinib (HQP1351) for patients with chronic myeloid leukemia (CML-CP) (with and without T315I mutation) who have been treated in the past. Based on this approval, this trial will be the first phase 3 trial of olevatinib approved by the US FDA for global registration. The study will begin in the first half of 2024.